Peripartale Kardiomyopathie

Die peripartale Kardiomyopathie ist eine seltene, aber potenziell lebensbedrohliche Erkrankung, die gegen Ende oder nach der Schwangerschaft auftritt. Die rechtzeitige Diagnose ist überlebensnotwendig. Das Wissen um die Symptomatik und Risikofaktoren hilft bei der Abgrenzung von sonstigen mit der Schwangerschaft einhergehenden Beschwerden. Auch die Zeit nach der Erkrankung ist eine Herausforderung für die Betreuung der betroffenen Frau.

• Literatur

• 1 Regitz-Zagrosek V. et al., Cardiovascular diseases in pregnancy. Dtsch Arztebl Int, 2011; 108 (16) p. 267-73
• 2 Siu S.C. et al., Prospective multicenter study of pregnancy outcomes in women with heart disease. Circulation, 2001; 104 (05) p. 515-21
• 3 Siu S.C. et al., Risk and predictors for pregnancy-related complications in women with heart disease. Circulation, 1997; 96 (09) p. 2789-94
• 4 Sliwa K. et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail, 2010; 12 (08) p. 767-78
• 5 Hull E, Hafkesbring E. “Toxic” postpartal heart disease. New Orleans Med Surg J., 1937; 89 p. 550
• 6 Ritchie C. Clinical contribution to the pathology, diagnosis and treatment of certain chronic diseases of the heart. Edinb Med Surg J., 1849; 2 p. 333
• 7 Regitz-Zagrosek V. et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J, 2011; 32 (24) p. 3147-97
• 8 Sliwa K. et al. Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy (PPCM): EURObservational Research Programme in conjunction with the Heart Failure Association of the European Society of Cardiology Study Group on PPCM. Eur J Heart Fail, 2017; 19 (09) p. 1131-1141
• 9 Tsang W, Lang RM. Peripartum cardiomyopathy: Etiology, clinical manifestations, and diagnosis, in. www.uptodate.com. 2018
• 10 Lampert MB, Lang RM. Peripartum cardiomyopathy. Am Heart J, 1995; 130 (04) p. 860-70
• 11 Sliwa K, Fett J, Elkayam U. Peripartum cardiomyopathy. Lancet, 2006; 368 ( 9536 ): p. 687-93
• 12 Bello N, Rendon ISH, Arany Z. The relationship between pre-eclampsia and peripartum cardiomyopathy: a systematic review and meta-analysis. J Am Coll Cardiol, 2013; 62 (18) p. 1715-1723
• 13 Hilfiker-Kleiner D. et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell, 2007; 128 (03) p. 589-600
• 14 Patten IS. et al. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature, 2012; 485 ( 7398 ): p. 333-8
• 15 Sliwa K, Mebazaa A. Possible joint pathways of early pre-eclampsia and congenital heart defects via angiogenic imbalance and potential evidence for cardio-placental syndrome. Eur Heart J, 2014; 35 (11) p. 680-2
• 16 Melvin KR. et al. Peripartum cardiomyopathy due to myocarditis. N Engl J Med, 1982; 307 (12) p. 731-4
• 17 Pearson GD. et al. Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review. Jama, 2000; 283 (09) p. 1183-8
• 18 Morales A. et al. Rare variant mutations in pregnancy-associated or peripartum cardiomyopathy. Circulation, 2010; 121 (20) p. 2176-82
• 19 van Spaendonck-Zwarts KY. et al. Titin gene mutations are common in families with both peripartum cardiomyopathy and dilated cardiomyopathy. Eur Heart J, 2014; 35 (32) p. 2165-73
• 20 van Spaendonck-Zwarts KY. et al. Peripartum cardiomyopathy as a part of familial dilated cardiomyopathy. Circulation, 2010; 121 (20) p. 2169-75
• 21 Elkayam U. et al. Pregnancy-associated cardiomyopathy: clinical characteristics and a comparison between early and late presentation. Circulation, 2005; 111 (16) p. 2050-5
• 22 Regitz-Zagrosek V. et al. Heart diseases in pregnancy. Clin Res Cardiol, 2008; 97 (09) p. 630-65
• 23 Ponikowski P. et al. 2016; ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. Rev Esp Cardiol (Engl Ed), 2016 . 69 (12) p. 1167
• 24 Sliwa K. et al. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. Circulation, 2010; 121 (13) p. 1465-73
• 25 Hilfiker-Kleiner D. et al. Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study. Eur Heart J, 2017; 38 (35) p. 2671-2679
• 26 Goland S, Elkayam U. Peripartum cardiomyopathy: approach to management. Curr Opin Cardiol, 2018; 33 (03) p. 347-353
• 27 Sliwa K. et al. Long-term prognosis, subsequent pregnancy, contraception and overall management of peripartum cardiomyopathy: practical guidance paper from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy. Eur J Heart Fail 2018
• 28 Haghikia A. et al. Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy. Basic Res Cardiol, 2013; 108 (04) p. 366
• 29 Libhaber E. et al. Low systolic blood pressure and high resting heart rate as predictors of outcome in patients with peripartum cardiomyopathy. Int J Cardiol, 2015; 190 p. 376-82
• 30 McNamara DM. et al. Clinical Outcomes for Peripartum Cardiomyopathy in North America: Results of the IPAC Study (Investigations of Pregnancy-Associated Cardiomyopathy). J Am Coll Cardiol, 2015; 66 (08) p. 905-14
• 31 Elkayam U. et al. Maternal and fetal outcomes of subsequent pregnancies in women with peripartum cardiomyopathy. N Engl J Med, 2001; 344 (21) p. 1567-71
• 32 Elkayam U. Risk of subsequent pregnancy in women with a history of peripartum cardiomyopathy. J Am Coll Cardiol, 2014; 64 (15) p. 1629-36
• 33 Hilfiker-Kleiner D. et al. Outcome of subsequent pregnancies in patients with a history of peripartum cardiomyopathy. Eur J Heart Fail, 2017; 19 (12) p. 1723-1728